England Approves Breakthrough COPD Treatment for 30,000

Nearly 30,000 people in England living with severe lung disease just got news that could transform their lives.

The National Institute for Health and Care Excellence has approved dupilumab, a groundbreaking treatment for chronic obstructive pulmonary disease that goes beyond managing symptoms to actually target what's causing the disease. For patients who've tried every inhaler available and still struggle to breathe, this represents the first real alternative in years.

COPD makes breathing increasingly difficult, causing chronic coughing, chest tightness, and devastating flare-ups that can last weeks. These episodes leave people unable to work, care for themselves, or do basic daily tasks. More than 1.2 million people in the UK live with COPD, and the disease triggers 130,000 emergency hospital visits in England every year.

What makes dupilumab different is how it works. Up to 40% of COPD patients have elevated levels of eosinophils, white blood cells that drive a specific type of inflammation. This new treatment blocks two key proteins responsible for that inflammation, addressing a root cause rather than just easing symptoms.

Patients inject themselves at home every two weeks using a pre-filled pen. Clinical trials showed the treatment reduced severe flare-ups by around 30% while significantly improving lung function and breathing. People reported being able to do more, feel better, and regain independence they'd lost.

The financial impact matters too. If half of eligible patients receive dupilumab, England could see 3,600 fewer COPD attacks and save £16.5 million. The treatment also reduces reliance on steroids, which commonly treat flare-ups but cause serious side effects with repeated use.

Adults qualify for dupilumab if they have raised eosinophil levels, experienced at least one severe flare-up or two moderate ones in the past year, and remain uncontrolled despite maximum inhaler therapy. NHS England negotiated a deal with manufacturer Sanofi to ensure the treatment offers value while reaching patients who need it most.

The Ripple Effect

This approval reaches beyond the 30,000 people who'll receive dupilumab immediately. It marks the first time a biologic therapy has successfully targeted COPD's underlying mechanisms, opening the door for more research into personalized treatments. Fewer hospital admissions mean less strain on emergency departments, freeing resources for other patients. And for families watching loved ones struggle to breathe, it offers something that's been in short supply: genuine hope for better days ahead.

Helen Knight, NICE's Director of Medicines Evaluation, called the approval "a significant milestone" that delivers both better outcomes for patients and better value for the NHS.

For thousands of people whose lungs have made every breath a battle, help is finally on the way.